20 Drugs the FDA Is Watching

First New Quarterly Report IDs Drug Side Effects Under FDA Investigation

Medically Reviewed by Louise Chang, MD on September 05, 2008
From the WebMD Archives

Sept. 5, 2008 -- The FDA is "evaluating" new adverse-event reports for 20 drugs, the agency announced today.

A 2007 federal law requires the FDA to disclose all its investigations into reports of possibly drug-related adverse events. Today's list is the first of this series of quarterly reports.

The list includes adverse events reported between Jan. 1 and March 31, 2008. FDA officials say it will be "weeks or months" before more recent reports are made.

All of the reports on the list come from the FDA's early-warning system for drugs already on the market. This Adverse Event Reporting System (AERS) collects reports from patients, hospitals, doctors, and drug companies about suspicious problems that might -- or might not -- be related to a medication.

Just because a drug is on the list doesn't mean it isn't safe -- or even that it caused the suspected problem. Nobody should stop taking a drug just because it's on the list, the FDA says.

"If a drug is listed, it means we have begun an analysis to see if there is a safety problem that requires further evaluation," Gerald Dal Pan, MD, MPH, director of the FDA office of surveillance and epidemiology, said at a news conference.

When that evaluation is done, the FDA will either issue further warnings or an all-clear, Dal Pan said.

Here's the list of drugs and the "adverse events" -- side effects -- reported to the AERS database:

Product Name: Active Ingredient (Trade)
or Product Class

Potential Signal of Serious Risk/New Safety Information

Arginine Hydrochloride Injection (R-Gene 10)

Pediatric overdose due to labeling / packaging confusion

Desflurane (Suprane)

Cardiac arrest (heart stops working)

Duloxetine (Cymbalta)

Urinary retention

Etravirine (Intelence)

Hemarthrosis (blood in a joint)

Fluorouracil Cream (Carac) and Ketoconazole Cream (Kuric)

Adverse events due to name confusion


Anaphylactic-type (life-threatening allergic) reactions

Icodextrin (Extraneal)

Hypoglycemia (low blood sugar)

Insulin U-500 (Humulin R)

Dosing confusion

Ivermectin (Stromectol) and Warfarin

Drug interaction

Lapatinib (Tykerb)

Hepatotoxicity (liver toxicity)

Lenalidomide (Revlimid)

Stevens-Johnson syndrome (a deadly drug reaction)

Natalizumab (Tysabri)

Skin melanomas (deadly skin cancer)

Nitroglycerin (Nitrostat)

Overdose due to labeling confusion

Octreotide Acetate Depot (Sandostatin LAR)

Ileus (bowels not moving)

Oxycodone Hydrochloride Controlled-Release (OxyContin)

Drug misuse, abuse, and overdose

Perflutren Lipid Microsphere (Definity)

Cardiopulmonary reactions (lung/heart problems)

Phenytoin Injection (Dilantin)

Purple glove syndrome (discoloration, pain, and swelling of the hand that may lead to amputation)

Quetiapine (Seroquel)

Overdose due to sample pack labeling confusion

Tebivudine (Tyzeka)

Peripheral neuropathy (tingling or numbness in the extremities)

Tumor Necrosis Factor (TNF) Blockers

Cancers in children and young adults


The report does not say how many people were affected by these possible drug reactions, nor does it give any indication of their severity.

"Our safety evaluators will look at the seriousness of the event, whether we are seeing greater numbers of a certain kind of event we should not expect, whether there is something new and not known about the drug, or whether this is something known but which may require refinement of our knowledge," Dal Pan said.

"This extends our commitment to keep the public and the health care community informed of what we are evaluating," Paul Seligman, MD, MPH, FDA associate director of safety policy and communication, said at the news conference.

Show Sources


FDA, "Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS), January - March 2008," posted on the FDA web site, Sept. 5, 2008.

News release, FDA

Gerald Dal Pan, MD, MPH, director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research (CDER), FDA.

Paul Seligman, MD, MPH, associate director of Safety Policy and Communication, CDER, FDA.

© 2008 WebMD, LLC. All rights reserved. View privacy policy and trust info